

02/14/02

Please type a plus sign (+) inside this box



02-15-02

A

UTILITY PATENT APPLICATION TRANSMITTAL

only for new nonprovisional applications under 37 CFR 1.53(b)

| | |
|------------------------|------------------------------------------------|
| Attorney Docket No. | JAB-1694 |
| First Inventor | Jean F.A. Lacrampe et al. |
| Title | INTERLEUKIN-5 INHIBITING 6-AZAUACIL DERIVATIVE |
| Express Mail Label No. | TB56851074US |

02/14/02

02/14/02

APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.
3. ☒ Specification [Total Pages 162]
(Preferred arrangement set forth below)
 - Descriptive Title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☐ Drawing(s) (35 USC 113) [Total Sheets]
5. Oath or Declaration [Total Pages 4]
 - a. ☒ Unexecuted (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. ☐ Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ paper
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure Statement
(IDS)/PTO-1449 ☒ Copies of IDS Citations
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Request and Certifications under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other

18. ☒ If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☒ Continuation-in-Part (CIP) of prior application No.: 10/_____, filed February 5, 2002.

Prior application information: Examiner

Group Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 000027777 or ☐ Correspondence Address below

Name: Philip S. Johnson, Esq.
Address: Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003 USA

20. TELEPHONE CONTACT

Please direct all telephone calls or telefaxes to Ellen Ciabrone Coletti at:
Telephone: (732) 524-2359 Fax: (732) 524-2808

21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

| | | |
|-----------|------------------------|----------------|
| NAME | Ellen Ciabrone Coletti | Reg. No. 34140 |
| SIGNATURE | | |
| DATE | February 14, 2002 | |

FEE TRANSMITTAL*Complete if Known*

| | |
|------------------------|---------------------------|
| Application Number | |
| Filing Date | |
| First Named Inventor | Jean F.A. Lacrampe et al. |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | JAB-1694 |


FEE CALCULATION

CLAIMS AS FILED

| (1) | (2) | (3) | (4) | (5) |
|---------------------------|--------------------------|--------------|------------|-----------------------|
| FOR: | NUMBER FILED | NUMBER EXTRA | RATE | BASIC FEE \$740.00 |
| TOTAL CLAIMS | 16 - 20 = | 0 | x 18.00 | \$ 0.00 |
| INDEPENDENT CLAIMS | 3 - 3 = | 0 | x 84.00 | \$ 0.00 |
| MULTIPLE DEPENDENT CLAIMS | <input type="checkbox"/> | N/A | \$280.00 | |
| | | | TOTAL FEES | \$ 740.00 |

METHOD OF PAYMENT

- ☒ Please charge Deposit Account No. 10-0750/JAB-1694/ECC in the amount of \$740.00. Three copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/JAB-1694/ECC. Three copies of this sheet are enclosed.

| | | |
|-----------------------|-----------------------------------------------------------------------------------|------------------------------------|
| SUBMITTED BY: | | <i>Complete (if applicable)</i> |
| Typed or Printed Name | Ellen Ciarrbone Coletti | Reg. No. 34,140 |
| Signature |  | Deposit Account No. 10-0750 |
| | Date: 2/14/02 | |

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

Applicant: Jean F.A. Lacrampe, Eddy J.E. Freyne, Frederick D.
Deroose, Jerome Fortin and Erwin Coesemans

For : INTERLEUKIN-5 INHIBITING 6-AZAUACIL DERIVATIVES

Express Mail Certificate

"Express Mail" mailing number: TB568851074US

Date of Deposit: February 14, 2002

I hereby certify that this complete continuation-in-part application, including specification pages, claims, preliminary amendment and an Information Disclosure Statement, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

A Combined Declaration and Power of Attorney will be submitted to the United States Patent and Trademark Office upon receipt of the U.S. Serial Number for this patent application.

Karen Hall-Morgan

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)